Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)

Inclusion Criteria: * Signed and dated informed consent * Histological documentation of Soft Tissue Sarcoma,including Synovial sarcoma、Leiomyosarcoma、Alveolar soft part sarcoma、Undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma、Adipocytic Tumors、Fibrosarcoma、Clear cell sarcoma、Epithelioid sarcoma，With measurable disease. * Within the past 6 months, using at least one failure of chemotherapy regimens (including anthracycline-based) in treating patients(except alveolar soft part sarcoma) * 18-70years,ECOG PS:0-1,Life expectancy of more than 3 months * Main organs function is normal * The woman patients of childbearing age who must agree to take contraceptive methods (e.g. intrauterine device, contraceptive pill or condom) during the research and within another 6 months after it; who are not in the lactation period and examined as negative in blood serum test or urine pregnancy test within 7 days before the research; The man patients who must agree to take contraceptive methods during the research and within another 6 months after it Exclusion Criteria: * Prior treatment with Anlotinib * With pleural effusion or ascites, cause respiratory syndrome * Accepted the vascular endothelial growth inhibitor class targeted drug treatment of patients * Plan to take systemic anti-tumor therapy within 4 weeks before grouping or during the medicine-taking period of this research, including Cytotoxic Therapy, Signal Transduction Inhibitor, and Immunotherapy (or who use Mitomycin C within 6 weeks before taking the treatment with experimental drug); The patients who have already taken Extended Field Radiotherapy (EF-RT) within 4 weeks before grouping or Limited Field Radiotherapy with proposed assessment of nidus within 2 weeks before grouping * Symptoms of brain metastases cannot be controlled and treated within less than 2 months * With severe and failed to controlled diseases * Occurred venous thromboembolic events within 6 months